Marchés français ouverture 5 h 4 min
  • Dow Jones

    31 176,01
    -12,37 (-0,04 %)
     
  • Nasdaq

    13 530,92
    +73,67 (+0,55 %)
     
  • Nikkei 225

    28 646,99
    -109,87 (-0,38 %)
     
  • EUR/USD

    1,2179
    +0,0006 (+0,05 %)
     
  • HANG SENG

    29 749,56
    -178,20 (-0,60 %)
     
  • BTC-EUR

    25 131,53
    +624,59 (+2,55 %)
     
  • CMC Crypto 200

    604,19
    -75,72 (-11,14 %)
     
  • S&P 500

    3 853,07
    +1,22 (+0,03 %)
     

Global Preclinical Imaging (In-VIVO) Industry

ReportLinker
·11 min de lecture

Global Preclinical Imaging (In-VIVO) Market to Reach US$1. 1 Billion by the Year 2027. Amid the COVID-19 crisis, the global market for Preclinical Imaging (In-VIVO) estimated at US$782. 5 Million in the year 2020, is projected to reach a revised size of US$1.

New York, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Preclinical Imaging (In-VIVO) Industry" - https://www.reportlinker.com/p05959765/?utm_source=GNW
1 Billion by 2027, growing at a CAGR of 4.8% over the period 2020-2027.Preclinical imaging modalities, one of the segments analyzed in the report, is projected to grow at a 5.2% CAGR to reach US$681.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Preclinical imaging reagents segment is readjusted to a revised 4.2% CAGR for the next 7-year period. This segment currently accounts for a 38.9% share of the global Preclinical Imaging (In-VIVO) market.

The U.S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 4.5% CAGR for the Period of 2020-2027

The Preclinical Imaging (In-VIVO) market in the U.S. is estimated at US$230.5 Million in the year 2020. The country currently accounts for a 29.46% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$191.7 Million in the year 2027 trailing a CAGR of 4.5% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR while Rest of European market (as defined in the study) will reach US$191.7 Million by the year 2027.We bring years of research experience to this 9th edition of our report. The 122-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Aspect Imaging

  • Bruker Corporation

  • FUJIFILM Holdings Corporation

  • LI-COR, Inc. (LI-COR Biosciences)

  • Mediso Ltd.

  • MILabs BV

  • Miltenyi Biotec GmbH

  • MR Solutions Ltd.

  • PerkinElmer, Inc.

  • Trifoil Imaging, Inc.




Read the full report: https://www.reportlinker.com/p05959765/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Preclinical Imaging (In-VIVO) Competitor Market Share Scenario
Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2027

Table 2: World Historic Review for Preclinical Imaging
(In-VIVO) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 3: World 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2012, 2018 & 2027

Table 4: World Current & Future Analysis for Preclinical
imaging modalities by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2027

Table 5: World Historic Review for Preclinical imaging
modalities by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 6: World 15-Year Perspective for Preclinical imaging
modalities by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2018 & 2027

Table 7: World Current & Future Analysis for Preclinical
imaging reagents by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2027

Table 8: World Historic Review for Preclinical imaging reagents
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017

Table 9: World 15-Year Perspective for Preclinical imaging
reagents by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Preclinical Imaging (In-VIVO) Market Share (in %) by
Company: 2018 & 2027
Market Analytics
Table 10: USA Current & Future Analysis for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents - Independent Analysis of Annual
Sales in US$ Million for the Years 2018 through 2027

Table 11: USA Historic Review for Preclinical Imaging (In-VIVO)
by Segment - Preclinical imaging modalities and Preclinical
imaging reagents Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 12: USA 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

CANADA
Table 13: Canada Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 14: Canada Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 15: Canada 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

JAPAN
Table 16: Japan Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 17: Japan Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 18: Japan 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

CHINA
Table 19: China Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 20: China Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 21: China 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

EUROPE
Market Facts & Figures
European Preclinical Imaging (In-VIVO) Market: Competitor
Market Share Scenario (in %) for 2018 & 2027
Market Analytics
Table 22: Europe Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2027

Table 23: Europe Historic Review for Preclinical Imaging
(In-VIVO) by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 24: Europe 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2018 & 2027

Table 25: Europe Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 26: Europe Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 27: Europe 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

FRANCE
Table 28: France Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 29: France Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 30: France 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

GERMANY
Table 31: Germany Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 32: Germany Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 33: Germany 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

ITALY
Table 34: Italy Current & Future Analysis for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 35: Italy Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 36: Italy 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

UNITED KINGDOM
Table 37: UK Current & Future Analysis for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents - Independent Analysis of Annual
Sales in US$ Million for the Years 2018 through 2027

Table 38: UK Historic Review for Preclinical Imaging (In-VIVO)
by Segment - Preclinical imaging modalities and Preclinical
imaging reagents Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 39: UK 15-Year Perspective for Preclinical Imaging
(In-VIVO) by Segment - Percentage Breakdown of Value Sales for
Preclinical imaging modalities and Preclinical imaging reagents
for the Years 2012, 2018 & 2027

REST OF EUROPE
Table 40: Rest of Europe Current & Future Analysis for
Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging
modalities and Preclinical imaging reagents - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 41: Rest of Europe Historic Review for Preclinical
Imaging (In-VIVO) by Segment - Preclinical imaging modalities
and Preclinical imaging reagents Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017

Table 42: Rest of Europe 15-Year Perspective for Preclinical
Imaging (In-VIVO) by Segment - Percentage Breakdown of Value
Sales for Preclinical imaging modalities and Preclinical
imaging reagents for the Years 2012, 2018 & 2027

ASIA-PACIFIC
Table 43: Asia-Pacific Current & Future Analysis for
Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging
modalities and Preclinical imaging reagents - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 44: Asia-Pacific Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 45: Asia-Pacific 15-Year Perspective for Preclinical
Imaging (In-VIVO) by Segment - Percentage Breakdown of Value
Sales for Preclinical imaging modalities and Preclinical
imaging reagents for the Years 2012, 2018 & 2027

REST OF WORLD
Table 46: Rest of World Current & Future Analysis for
Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging
modalities and Preclinical imaging reagents - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 47: Rest of World Historic Review for Preclinical Imaging
(In-VIVO) by Segment - Preclinical imaging modalities and
Preclinical imaging reagents Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 48: Rest of World 15-Year Perspective for Preclinical
Imaging (In-VIVO) by Segment - Percentage Breakdown of Value
Sales for Preclinical imaging modalities and Preclinical
imaging reagents for the Years 2012, 2018 & 2027

IV. COMPETITION
Total Companies Profiled: 65
Read the full report: https://www.reportlinker.com/p05959765/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001